Phaseline

Companies › Kissei Pharmaceutical

Kissei Pharmaceutical: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 2; Oncology, Neurology, Genitourinary; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Rovatirelin (KPS-0373)
Thyrotropin-releasing hormone receptor agonist
TRHRPhase 3Spinocerebellar DegenerationMar 2027
Linzagolix (KLH-2109)
Gonadotropin-releasing hormone receptor antagonist
GNRHRPhase 3EndometriosisNov 2027
Olutasidenib
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 2Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid LeukemiaSep 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07040137Rovatirelin (KPS-0373)Phase 3Spinocerebellar DegenerationNeurologyMar 2027
NCT07015268Linzagolix (KLH-2109)Phase 3EndometriosisGenitourinaryNov 2027
NCT07604064OlutasidenibPhase 2Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid LeukemiaOncologySep 2030

Targets

IDH1 (1) TRHR (1) GNRHR (1)

Companies with the same targets

Servier Eli Lilly Nuvation Bio Bristol-Myers Squibb Servier Affaires Médicales Hutchmed Rigel Pharmaceuticals Servier Bio-Innovation Novartis Daiichi Sankyo

Companies built like this

Woolsey Pharmaceuticals Servier Italfarmaco Shanghai Jiaolian Drug Research and Development SK Life Science

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.